Intrapericardial cisplatin combined with oral colchicine resulting in long term control of malignant pericardial effusion in the course of metastatic renal cancer

The authors declare no financial disclosure

Abstract

Introduction: Neoplastic pericardial effusion (NPE) represents a common cause of morbidity and mortality in cancer patients. Over 60% of NPE is diagnosed in the course of lung cancer, breast cancer and hematologic malignancies [1–3]. NPE presents frequently as cardiac tamponade, requiring urgent pericardiocentesis or pericardiotomy, with subsequent pericardial fluid drainage [4, 5]. Despite high effectiveness of such procedures, the recurrence of effusion was noted in 30–60% of patients [6, 7]. Intrapericardial cisplatin therapy was found to be an effective method of prevention of NPE recurrence in lung cancer patients [8, 9]. The efficacy of such treatment in other solid tumors is poorly documented.

Colchicine, an anti-inflammatory drug, inhibits neutrophils motility and activity at the site of inflammation, decreases the production of IL-1 by monocytes and reduces the release of lysozymes by phagocytes [10]. It is currently recommended as first-line therapy of acute and recurrent benign pericarditis [4]. The COPPS study proved colchi-
Cine efficacy in prevention of post-pericardiotomy syndrome [11]. The role of colchicine in NPE has not been established yet.

The present case report concerns successful intra-pericardial cisplatin treatment combined with oral colchicine therapy in the patient with NPE due to metastatic renal cancer.

Case presentation

An 82-year-old man, treated for arterial hypertension and hypothyroidism, with a history of right-sided nephrectomy in 2003 due to clear-cell renal carcinoma, with metastatic lung disease treated with sunitinib (2009–2012) and everolimus (2012–2013) was admitted to the Intensive Care Unit (ICU) in June 2013 because of threatening cardiac tamponade. Two weeks earlier the patient had noticed a decrease in exercise tolerance, accompanied by a dry cough.

On admission to ICU the man was in poor general condition, with marked weight loss about 5 kg in 3 months (BMI 18). Physical examination revealed blood pressure 150/80, heart rate 90/min. On auscultation — dull heart sounds, and wheezing over the lung fields were heard. Liver was enlarged, palpable 4 cm below the right costal margin. Orthopnea and hemodynamic instability were not found.

Laboratory analysis revealed anemia (E 3.85 × 10^12/l, hemoglobin 9.4 g%), elevated levels of D-dimer (2674 ug/l), increased GGTP (95 U/l) and NT-proBNP (541 pg/ml). TSH was 2.6 mIU/ml, fT4 — 17.8 pmol/l (within normal limits).

Chest X-ray showed significantly enlarged cardiac silhouette, bilateral pleural effusion, and bilateral lung infiltrative lesions, suggesting metastatic lung disease (Fig. 1).

ECG revealed sinus rhythm of about 85/min., left anterior hemi block, right branch bundle block. Low QRS voltage as well as signs of electrical alternans were also recorded (Fig. 2).

Figure 1. Chest X-ray: significantly enlarged cardiac silhouette, bilateral pleural effusion, and bilateral lung infiltrative lesions, suggesting metastatic lung disease

Figure 2. ECG Sinus rhythm about 85 per minute. Left axis pathological. Left anterior hemiblock. Right bundle branch block. Electrical alternans
Małgorzata Dybowska et al., Intrapericardial cisplatin combined with oral colchicine resulted in long term control

Bedside echocardiography demonstrated the presence of pericardial fluid (a layer of 9–16 mm), with elements of fibrin, surrounding the whole heart. Moreover, right atrium diastolic collapse was noted (Fig. 3).

Threatening cardiac tamponade was diagnosed. As the amount of fluid was not very large and the widest layer was found over the right ventricle, the patient was proposed subxiphoid pericardiotomy, but he was initially reluctant.

On the second day he experienced an episode of atrial fibrillation with a decrease in blood pressure to 90/60 mm Hg. Urgent subxiphoid pericardiotomy was performed, 1000 ml of bloody fluid was removed. Several pink nodules were found on the inner surface of pericardium. Histological examination of pericardial specimen revealed multiple carcinoma cell clusters — *Ca clarocellulare*. Pericardial fluid cytological examination was positive. Pericardial fluid cultures were negative. Thus NPE was confirmed.

Due to persistent high pericardial drainage in subsequent days (250–450 ml of bloody fluid/day), intrapericardial cisplatin therapy was commenced. The drug was given on 5 consecutive days. Each dose consisted of 10 mg of cisplatin dissolved in 20 ml of 0.9% NaCl administered by a catheter into the pericardial sac. The drain was clamped for 24 hours, then the fluid was removed and the dose of cisplatin was repeated. Starting from the first day after surgery, colchicine 0.5 mg/day was introduced. No complications of treatment were observed.

Control echocardiographic examination confirmed significant resolution of PF. No signs of pericardial constriction were found (Fig. 4). Control chest X-ray examination disclosed the decrease of cardiac dimensions and partial regression of pleural fluid (Fig. 5).

On the 13th postoperative day pericardial drain was removed. The patient was discharged, and he continued the treatment with colchicine. Despite gradual progression of renal cell carcinoma, pericardial disease has been well controlled until death. Last echocardiographic examination revealed the presence of additional echoes in the left atrium and left ventricle, representing probably intracardiac metastatic lesions. The patient survived 12 months from intrapericardial cisplatin therapy.

**Discussion**

The ideal treatment for NPE ensures the complete removal of fluid, relief of symptoms, prevention of recurrent effusion, influence on the local neoplastic disease and survival benefit [12].
Pericardiectomy with PF drainage was not a sufficient method of therapy in the presented patient due to subsequent large daily production of PF.

Improvement of local disease control and prevention of PF recurrence may be achieved by intrapericardial instillation of cytotoxic agents such as cisplatin, thiopeta, bleomycin [8, 9, 13–16]. Recently, intrapericardial activity of anti-angiogenic factor — bevacizumab was reported in NPE [17].

The rationale for intrapericardial instillation of antineoplastic drug is to provide its higher concentration than those achieved in the course of systemic therapy. So far no randomized controlled trials evaluating the efficacy and safety of intrapericardial chemotherapy have been performed, and that is why all recommendations are based only on the results of small observational studies.

Intrapericardial treatment tailored to the type of the tumor indicate that administration of cisplatin has been most efficient in NPE due to lung cancer [8, 9, 13], and intrapericardial instillation of thiopeta has been more effective in NPE due to breast cancer [18, 19].

There is no evidence for the efficacy of systemic chemotherapy with cisplatin in patients with renal cell carcinoma, and the experience with intrapericardial therapy in this type of tumor is lacking. Nevertheless, we decided to apply intrapericardial cisplatin, having in mind its good therapeutic and safety profile in other solid tumors.

Colchicine was introduced as an early add-on therapy to improve local anti-inflammatory effect. There is not much data concerning colchicine therapy in NPE. Ng et al. [20] reported successful colchicine use in NPE that developed in the course of malignant myeloma [20]. In this patient, pericardiocentesis, followed by surgical approach with the creation of pericardial window, were ineffective. Colchicine at a dose of 1 mg/day, stopped pericardial drainage after 5 days of treatment.

In our patient intrapericardial cisplatin administration and colchicine therapy resulted in gradual, almost complete resolution of pericardial fluid. Moreover, prolonged colchicine therapy successfully prevented effusion recurrence for the next 12 months.

No side effects of colchicine treatment were observed in our patient. Prolonged colchicine therapy has been well tolerated in patients with other diseases such as familial Mediterranean fever or in recurrent benign pericarditis [21, 22]. Nevertheless, it is important to adjust the daily dose of the drug to the patient’s age and weight [4]. The dose of colchicine was reduced in our patient to 0.5 mg/d, due to low weight and advanced age.

Drug interactions have to be taken into consideration in the course of prolonged colchicine use, especially with macrolides and statins [4]. The interaction between TKI-inhibitors and colchicines has been also reported, thus lowering its dose to 0.3 mg/day was proposed [23].

Summary

Intrapericardial cisplatin therapy combined with oral colchicine demonstrated an excellent and prolonged local anti-inflammatory effect in cardiac tamponade due to metastatic renal cell carcinoma.

Conflict of interest

The authors declare no financial disclosure.

References:


